N-protected heterocyclic compound, preparation method thereof and method for using same in preparing C-nucleoside derivatives

By using the direct reaction of heterocyclic compounds protected by N-benzyloxycarbonyl or N-tert-butoxycarbonyl and ribosolide, the problems of long and high cost of synthesis of existing C-nucleoside analogs are solved, and high efficiency is achieved , low-cost C-nucleoside derivative synthesis significantly improves yield and purity.

CN113248508BActive Publication Date: 2024-12-06ANHUI NUOQUAN PHARM CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202110190537.9
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2020-03-10
Filing Date
2021-02-18
Publication Date
2024-12-06
Estimated Expiration
2041-02-18

AI Technical Summary

Technical Problem

The existing methods for synthesis of C-nucleoside analogs have problems such as expensive raw materials, low yields or long routes, and it is difficult to provide methods with short synthetic routes, low cost and high yields.

Method used

Heterocyclic compounds protected by N-benzyloxycarbonyl or N-tert-butoxycarbonyl are directly synthesized by amino protection reaction and ribolactone addition, avoiding temporary protection of amino groups and halogenation. Reactions simplify the synthesis route and improve reaction efficiency and yield.

Benefits of technology

It realizes efficient synthesis of C-nucleoside derivatives, shortens the synthesis route, reduces costs, improves yield and product purity, and is easy to purify intermediates, suitable for industrial production.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure FT_1
    Figure FT_1
  • Figure BDA0002943960810000011
    Figure BDA0002943960810000011
  • Figure BDA0002943960810000021
    Figure BDA0002943960810000021
Patent Text Reader

Abstract

The present invention provides an N-protected heterocyclic compound, a preparation method thereof and a method for preparing a C-nucleoside derivative thereof. Specifically, the present invention provides a method for preparing a C-nucleoside derivative using a heterocyclic compound protected by N-benzyloxycarbonyl or N-tert-butyloxycarbonyl. The method of the present invention does not require halogenation, does not require temporary amino protection, and directly uses an organic lithium or organic magnesium compound to remove the proton of the heterocyclic compound, and adds to a ribolactone. The method of the present invention not only shortens the synthetic route of the C-nucleoside derivative, but also, in the absence of a halogen atom as a substituent, the reaction of the heterocyclic compound with the ribolactone obtains a significantly improved yield.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of chemical synthesis, and in particular to an N-protected heterocyclic compound, a preparation method thereof and a method for using the same to prepare a C-nucleoside derivative. Background Art

[0002] C-nucleosides have been widely studied and applied due to their good drugability. Some C-nucleoside structures show good antiviral or antitumor pharmacological activities. Currently, there are methods for synthesizing C-nucleoside analogs, but the synthesis of some special C-nucleosides is still difficult.

[0003] In 2012, Gilead reported that bases 1a and 1c, after temporary silicon protection, can be added and reduced with ribolactone to obtain C-nucleoside analogs 3a and 3c [Bioorganic & Medicinal Chemistry Letters 2012, 22 (12), 4127-4132; Journal of Medicinal Chemistry 2014, 57 (5), 1812-1825]. However, the yield from 1a to 3a or 3c was less than 20%.

[0004]

[0005] In 2017, Gilead reported an improvement in this method: starting from base 1b, C-nucleoside analog 3a can be obtained more reliably [Journal of Medicinal Chemistry 2017, 60(5), 1648-1661.], but the yield from 1b to 3a was less than 40%.

[0006]

[0007] In 2014, Biota Scientific Management and Boehringer Ingelheim reported a more complex synthesis method for C-nucleoside analogs 3d and 3e [ACS Medicinal Chemistry Letters 2014, 5(6), 679-684].

[0008]

[0009] In 2018, Chen Yuelei et al. reported an improved method using N-tert-butyloxycarbonyl-protected heterocyclic compounds to prepare C-nucleoside analogs 3-1 [Organic Chemistry Frontiers 2018, 5, 1992-1999], with a higher yield than the above literature.

[0010]

[0011] However, the above synthesis methods of C-nucleoside analogs still have problems such as expensive raw materials, low yield or long route.

[0012] Therefore, there is an urgent need in the art to provide a method for preparing C-nucleoside derivatives with a short synthetic route, low cost and high yield. Summary of the invention

[0013] The purpose of the present invention is to provide a method for preparing C-nucleoside derivatives with short synthetic route, low cost and high yield.

[0014] Another object of the present invention is to provide an intermediate of a class of C-nucleoside derivatives and applications thereof.

[0015] Another object of the present invention is to provide a method for preparing remdesivir with a short synthetic route, low cost and high yield.

[0016] In a first aspect of the present invention, there is provided a method for preparing a compound of formula 6, comprising the steps of:

[0017] (i) subjecting the amino group of the compound of formula 1 to an amino protection reaction to obtain a compound of formula 2;

[0018]

[0019] (ii) reacting the compound of formula 2 with the compound of formula A to obtain a compound of formula 3;

[0020]

[0021] Then, step (iii) or (iii') is performed,

[0022] wherein (iii) the hydroxyl group of the compound of formula 3 undergoes a substitution reaction to obtain a compound of formula 4; and

[0023]

[0024] (iii') the hydroxyl group of the compound of formula 3 undergoes a substitution reaction to obtain a compound of formula 4a;

[0025]

[0026] and step (iv) or (iv'),

[0027] wherein (iv) the compound of formula 4 undergoes a complete deprotection reaction to obtain a compound of formula 6;

[0028]

[0029] (iv') the compound of formula 4a undergoes complete deprotection reaction to obtain a compound of formula 6;

[0030]

[0031] In the above formulas,

[0032] R is selected from the group consisting of tert-butyl or benzyl; and

[0033] R 1 and R 2 Independently selected from the group consisting of substituted or unsubstituted C6-C10 aryl, substituted or unsubstituted benzyl, substituted or unsubstituted naphthylmethyl, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C1-C6 alkylsilyl, or substituted or unsubstituted -Si(Ph)2-(C1-C6 alkyl);

[0034] Here, the "substituted" means that one or more (2, 3, 4, 5) hydrogen atoms on the group are replaced by a group selected from the group consisting of halogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, or C6-C10 aryl.

[0035] In another preferred embodiment, in step (i), the compound of formula 1 is reacted with the compound of formula D1.

[0036] (D1) and / or ROCOCl (D2)

[0037] In the formula,

[0038] R is selected from the group consisting of tert-butyl or benzyl.

[0039] In another preferred embodiment, R 1 and R 2 Independently selected from the following group: 2-naphthylmethyl, 1-naphthylmethyl, tert-butyldimethylsilyl, tert-butyldiphenylsilyl (TBDPS), triisopropylsilyl, triethylsilyl, benzyl, p-methoxybenzyl, benzyl substituted by halogen or C1-C6 straight or branched alkyl.

[0040] In another preferred embodiment, the method has one or more of the following features:

[0041] (i) in an inert solvent, subjecting the amino group of the compound of formula 1 to an amino protection reaction to obtain a compound of formula 2;

[0042] (ii) reacting the compound of formula 2 with the compound of formula A in an inert solvent in the presence of an organolithium and / or organomagnesium reagent to obtain a compound of formula 3;

[0043]

[0044] (iii) in an inert solvent, in the presence of an acid and a cyanating agent, the hydroxyl group of the compound of formula 3 undergoes a substitution reaction to obtain a compound of formula 4; or (iii') in an inert solvent, in the presence of an acid and a cyanating agent, the hydroxyl group of the compound of formula 3 undergoes a substitution reaction and an amino group deprotection reaction to obtain a compound of formula 4a; and / or

[0045] (iv) subjecting the compound of formula 4 to a deprotection reaction in an inert solvent to obtain a compound of formula 6; or (iv') subjecting the compound of formula 4a to a deprotection reaction in an inert solvent to obtain a compound of formula 6.

[0046] In another preferred embodiment, the compound of formula A is

[0047] In another preferred embodiment, in step (iii') or (iii'), the acid is independently selected from the following group: TMSOTf, trifluoromethanesulfonic acid, trifluoroacetic acid, boron trifluoride-ether complex, methanesulfonic acid.

[0048] In another preferred embodiment, the cyanation agent is selected from the group consisting of TMSCN, TBSCN, ZnCN, or a combination thereof.

[0049] In another preferred embodiment, the organic lithium reagent is an alkyl lithium.

[0050] In another preferred embodiment, the organic lithium reagent is selected from the following group: methyl lithium, sec-butyl lithium, tert-butyl lithium, LDA, or a combination thereof.

[0051] In another preferred embodiment, the organomagnesium reagent is selected from the group consisting of i-PrMgCl·LiCl (Turbo Grignard reagent), s-BuMgCl·LiCl (another Turbo Grignard reagent), TMPMgCl·LiCl (Knochel HauserBase), or a combination thereof.

[0052] In a second aspect of the present invention, there is also provided a method for preparing the compound of formula 6, comprising the steps of:

[0053] (i) subjecting the amino group of the compound of formula 1 to an amino protection reaction to obtain a compound of formula 2;

[0054]

[0055] (ii) reacting the compound of formula 2 with the compound of formula A to obtain a compound of formula 3;

[0056]

[0057] (iii) the hydroxyl group of the compound of formula 3 undergoes a substitution reaction to obtain a compound of formula 4;

[0058]

[0059] (iv) selectively deprotecting the compound of formula 4 to obtain a compound of formula 5; and

[0060]

[0061] (v) deprotecting the compound of formula 5 to obtain a compound of formula 6; and

[0062]

[0063] In the above formulas,

[0064] R is selected from the group consisting of tert-butyl or benzyl; and

[0065] R 1 and R 2 Independently selected from the group consisting of substituted or unsubstituted C6-C10 aryl, substituted or unsubstituted benzyl, substituted or unsubstituted naphthylmethyl, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C1-C6 alkylsilyl, or substituted or unsubstituted -Si(Ph)2-(C1-C6 alkyl);

[0066] Here, the "substituted" means that one or more (2, 3, 4, 5) hydrogen atoms on the group are replaced by a group selected from the group consisting of halogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, or C6-C10 aryl.

[0067] In another preferred embodiment, the method has one or more of the following features:

[0068] (i) in an inert solvent, subjecting the amino group of the compound of formula 1 to an amino protection reaction to obtain a compound of formula 2;

[0069] (ii) reacting the compound of formula 2 with the compound of formula A in an inert solvent in the presence of organolithium and / or organomagnesium to obtain a compound of formula 3;

[0070] (iii) in an inert solvent, in the presence of an acid and a cyanation agent, subjecting the hydroxyl group of the compound of formula 3 to a substitution reaction to obtain a compound of formula 4;

[0071] (iv) in an inert solvent, in the presence of a Lewis acid (preferably boron trichloride), subjecting the compound of formula 4 to a selective deprotection reaction to obtain a compound of formula 5; and / or

[0072] (v) In an inert solvent, in the presence of a Lewis acid or a protonic acid (preferably hydrochloric acid or trifluoroacetic acid), the compound of formula 5 undergoes a deprotection reaction to obtain a compound of formula 6.

[0073] In another preferred embodiment, the acid is selected from the following group: TMSOTf, trifluoromethanesulfonic acid, trifluoroacetic acid, boron trifluoride-ether complex, and methanesulfonic acid.

[0074] In another preferred embodiment, the cyanation agent is selected from the group consisting of TMSCN, TBSCN, ZnCN, or a combination thereof.

[0075] In the third aspect of the present invention, a method for preparing remdesivir is provided, the method comprising the steps of preparing compound 6 as described in any one of the first aspect of the present invention and the second aspect of the present invention.

[0076] In another preferred embodiment, the method further comprises the following steps:

[0077]

[0078] In a fourth aspect, the present invention further provides a method for preparing remdesivir, the method comprising the steps of:

[0079] (c) deprotecting the compound of formula 9a to obtain a compound of formula 10;

[0080]

[0081] In the formula, R is selected from the following group: tert-butyl or benzyl.

[0082] In another preferred embodiment, in step (c), the hydroxyl group deprotection reaction and the amino group deprotection reaction of the compound of formula 9a can be carried out step by step in any order or simultaneously.

[0083] In another preferred embodiment, in step (c), in an inert solvent or in the absence of a solvent, in the presence of a deprotecting agent, the compound of formula 9a undergoes a deprotection reaction to obtain a compound of formula 10.

[0084] In another preferred embodiment, the deprotecting agent is selected from the following group: sulfuric acid, hydrochloric acid, formic acid, acetic acid, p-toluenesulfonic acid, camphorsulfonic acid, methanesulfonic acid, trifluoroacetic acid, trifluoromethanesulfonic acid.

[0085] In another preferred embodiment, in step (c), the deprotection temperature is -20-50°C, preferably, -10-30°C.

[0086] In another preferred embodiment, in step (c), the inert solvent is water.

[0087] In another preferred embodiment, before step (c), the method further comprises the following steps:

[0088] (b) reacting the compound of formula 7a with the compound of formula 8 to obtain a compound of formula 9a;

[0089]

[0090] In the formula, Lg is selected from the following group: halogen, substituted or unsubstituted C6-C10 aryloxy;

[0091] Wherein, the "substituted" means that one or more hydrogen atoms (1, 2, 3, 4 or 5) in the group are replaced by a group selected from the following group: halogen, nitro; and

[0092] R is as defined above.

[0093] In another preferred embodiment, in step (b), in an inert solvent, in the presence of a magnesium salt, a lithium salt and / or an aluminum salt and a base, the compound of formula 7a reacts with the compound of formula 8 to obtain a compound of formula 9a; or

[0094] In an inert solvent, in the presence of a metal organic reagent, the compound of formula 7a reacts with the compound of formula 8 to obtain a compound of formula 9a.

[0095] In another preferred embodiment, the magnesium salt is selected from the group consisting of magnesium chloride, magnesium bromide, magnesium iodide, or a combination thereof.

[0096] In another preferred embodiment, the lithium salt is selected from the following group: lithium chloride, lithium bromide, lithium iodide, or a combination thereof.

[0097] In another preferred embodiment, the aluminum salt is aluminum trichloride.

[0098] In another preferred embodiment, the base is an organic base, preferably diisopropylethylamine, triethylamine, tributylamine, N-methylmorpholine, N-methylpiperidine, pyridine, 2,6-lutidine, or a combination thereof.

[0099] In another preferred embodiment, the metal organic reagent is selected from the following group: tert-butyl magnesium chloride, isopropyl magnesium chloride, isobutyl magnesium chloride, ethyl magnesium chloride, butyl lithium, sodium hydrogen, potassium tert-butoxide, sodium tert-butoxide, sodium isopentanolate, or a combination thereof.

[0100] In another preferred embodiment, before step (b), the method further comprises the following steps:

[0101] (a) reacting the compound of formula 5 with acetone and / or 2,2-dimethoxypropane to undergo hydroxyl protection reaction to generate a compound of formula 7a;

[0102]

[0103] Wherein, R is as defined above.

[0104] In another preferred embodiment, in step (a), in acetone and / or 2,2-dimethoxypropane, in the presence of a protonic acid, the compound of formula 5 undergoes a hydroxyl protection reaction with acetone and / or 2,2-dimethoxypropane to generate a compound of formula 7a.

[0105] In another preferred embodiment, the protonic acid is selected from the following group: sulfuric acid, p-toluenesulfonic acid, camphorsulfonic acid, methanesulfonic acid, trifluoromethanesulfonic acid, trifluoroacetic acid, or a combination thereof.

[0106] In another preferred embodiment, in step (a), the reaction temperature of the hydroxyl protection reaction is -10-100°C, preferably, 20-50°C.

[0107] In a fifth aspect, the present invention further provides a method for preparing remdesivir, characterized in that the method comprises the steps of:

[0108] (z) the compound of formula YY undergoes a deprotection reaction to generate a compound of formula 10;

[0109]

[0110] In the formula, R is selected from the following group: tert-butyl or benzyl.

[0111] In another preferred embodiment, in step (z), in an inert solvent or in the absence of a solvent, in the presence of a deprotecting agent, the compound of formula YY undergoes a deprotection reaction to generate a compound of formula 10.

[0112] In another preferred embodiment, in step (z), the inert solvent is an alcohol, preferably, a C1-C6 alkyl alcohol, more preferably, methanol, ethanol, isopropanol, or a combination thereof.

[0113] In another preferred embodiment, in step (z), the inert solvent is an ether, preferably tetrahydrofuran, 2-methyltetrahydrofuran, methyl tert-butyl ether, isopropyl ether, diethyl ether, ethylene glycol dimethyl ether, or a combination thereof.

[0114] In another preferred embodiment, in step (z), the inert solvent is a halogenated hydrocarbon, preferably dichloromethane, chloroform, 1,2-dichloroethane, or a combination thereof.

[0115] In another preferred embodiment, in step (z), the inert solvent is an aromatic hydrocarbon compound, preferably toluene, xylene, benzene, chlorobenzene, or a combination thereof.

[0116] In another preferred embodiment, the deprotecting agent is a protonic acid. Preferably, the protonic acid is selected from the following group: sulfuric acid, hydrochloric acid, formic acid, acetic acid, p-toluenesulfonic acid, camphorsulfonic acid, methanesulfonic acid, trifluoroacetic acid, trifluoromethanesulfonic acid, or a combination thereof.

[0117] In another preferred embodiment, in step (z), the inert solvent is water.

[0118] In another preferred embodiment, before step (z), the method further comprises the following steps:

[0119] (y) reacting a compound of formula 5 with a compound of formula 8 to produce a compound of formula YY;

[0120]

[0121] In the formula, Lg is selected from the following group: halogen, substituted or unsubstituted C6-C10 aryloxy;

[0122] Wherein, the "substituted" means that one or more hydrogen atoms (1, 2, 3, 4 or 5) in the group are replaced by a group selected from the group consisting of halogen, nitro;

[0123] R is as defined above.

[0124] In another preferred embodiment, in step (y), in an inert solvent, in the presence of a magnesium salt, a lithium salt and / or an aluminum salt and a base, the compound of formula 5 reacts with the compound of formula 8 to obtain a compound of formula YY; or

[0125] In an inert solvent, in the presence of a metal organic reagent, the compound of formula 5 reacts with the compound of formula 8 to obtain a compound of formula YY.

[0126] In a sixth aspect, the present invention provides a compound of formula M,

[0127]

[0128] In the formula,

[0129] G is selected from the following group: H or

[0130] Wherein, R is selected from the following group: tert-butyl or benzyl;

[0131] R 1 and R 2 Independently selected from the following group: H, substituted or unsubstituted C6-C10 aryl, substituted or unsubstituted benzyl, substituted or unsubstituted naphthylmethyl, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C1-C6 alkylsilyl, substituted or unsubstituted -Si(Ph)2-(C1-C6 alkyl), or two R1 together form -C(R4)2-;

[0132] R4 is independently selected from the following group: substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C2-C6 alkenyl, substituted or unsubstituted C2-C6 alkynyl, or two R4 together with the C atom to which they are attached form a substituted or unsubstituted 4-7 membered carbocyclic ring;

[0133] Here, the "substituted" means that one or more (2, 3, 4, 5) hydrogen atoms on the group are replaced by a group selected from the group consisting of halogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, or C6-C10 aryl.

[0134] In another preferred embodiment, the carbocyclic ring is a saturated carbocyclic ring.

[0135] In another preferred embodiment, two R4 are the same or different.

[0136] In another preferred embodiment, R4 is methyl.

[0137] In another preferred embodiment, the compound of formula M is selected from the following group:

[0138]

[0139]

[0140] In each formula, R is independently selected from the group consisting of tert-butyl or benzyl.

[0141] In a seventh aspect, the present invention provides a use of a compound of formula M for preparing a C-nucleoside derivative, or as an intermediate for preparing a C-nucleoside derivative.

[0142] In another preferred embodiment, the C-nucleoside derivative is selected from the following group: a compound of formula 3, a compound of formula 6, a compound of formula 7, a compound of formula 9 or remdesivir.

[0143] In an eighth aspect, the present invention provides a method for preparing remdesivir, comprising the steps of: using a compound of formula M as an intermediate or raw material in the preparation process.

[0144] In a ninth aspect, the present invention provides a method for preparing a compound of formula 4, comprising the steps of:

[0145] Substituting the hydroxyl group of the compound of formula 3 to obtain a compound of formula 4;

[0146]

[0147] In the formula,

[0148] R is selected from the group consisting of tert-butyl or benzyl; and

[0149] R 1 and R 2 Independently selected from the group consisting of substituted or unsubstituted C6-C10 aryl, substituted or unsubstituted benzyl, substituted or unsubstituted naphthylmethyl, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C1-C6 alkylsilyl, or substituted or unsubstituted -Si(Ph)2-(C1-C6 alkyl);

[0150] Here, the "substituted" means that one or more (2, 3, 4, 5) hydrogen atoms on the group are replaced by a group selected from the group consisting of halogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, or C6-C10 aryl.

[0151] In a tenth aspect, the present invention provides a method for preparing a compound of formula 5, comprising the steps of:

[0152] Subjecting the compound of formula 4 to a selective deprotection reaction to obtain a compound of formula 5; and

[0153]

[0154] In the formula,

[0155] R is selected from the group consisting of tert-butyl or benzyl; and

[0156] R 1 and R 2 Independently selected from the group consisting of substituted or unsubstituted C6-C10 aryl, substituted or unsubstituted benzyl, substituted or unsubstituted naphthylmethyl, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C1-C6 alkylsilyl, or substituted or unsubstituted -Si(Ph)2-(C1-C6 alkyl);

[0157] Here, the "substituted" means that one or more (2, 3, 4, 5) hydrogen atoms on the group are replaced by a group selected from the group consisting of halogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, or C6-C10 aryl.

[0158] In an eleventh aspect of the present invention, there is provided a method for preparing a compound of formula 7a, comprising the steps of:

[0159] The compound of formula 5 undergoes a hydroxyl protection reaction with acetone and / or 2,2-dimethoxypropane to generate a compound of formula 7a;

[0160]

[0161] wherein R is as defined above.

[0162] In another preferred embodiment, in step (a), in acetone and / or 2,2-dimethoxypropane, in the presence of a protonic acid, the compound of formula 5 undergoes a hydroxyl protection reaction with acetone and / or 2,2-dimethoxypropane to generate a compound of formula 7a.

[0163] In another preferred embodiment, the protonic acid is selected from the group consisting of sulfuric acid, hydrochloric acid, formic acid, acetic acid, p-toluenesulfonic acid, camphorsulfonic acid, methanesulfonic acid, trifluoroacetic acid, trifluoromethanesulfonic acid, or a combination thereof.

[0164] In a twelfth aspect of the present invention, there is provided a compound of formula 9a:

[0165]

[0166] Wherein, R is selected from the following group: tert-butyl or benzyl.

[0167] In a thirteenth aspect, the present invention provides a method for preparing a compound of formula 9a, comprising the steps of:

[0168] (b) reacting the compound of formula 7a with the compound of formula 8 to obtain a compound of formula 9a;

[0169]

[0170] In the formula, Lg is selected from the following group: halogen, substituted or unsubstituted C6-C10 aryloxy;

[0171] Wherein, the "substituted" means that one or more hydrogen atoms (1, 2, 3, 4 or 5) in the group are replaced by a group selected from the following group: halogen, nitro; and

[0172] R is as defined above.

[0173] In another preferred embodiment, Lg is selected from the following group: p-nitrophenoxy, pentafluorophenoxy or chlorine.

[0174] In another preferred embodiment, in step (b), in an inert solvent, in the presence of a magnesium salt, a lithium salt and / or an aluminum salt and a base, the compound of formula 7a reacts with the compound of formula 8 to obtain a compound of formula 9a; or

[0175] In an inert solvent, in the presence of a metal organic reagent, the compound of formula 7a reacts with the compound of formula 8 to obtain a compound of formula 9a.

[0176] In a fourteenth aspect, the present invention provides a compound of formula YY:

[0177]

[0178] Wherein, R is selected from the following group: tert-butyl or benzyl.

[0179] In a fifteenth aspect, the present invention provides a method for preparing a compound of formula YY, comprising the steps of:

[0180] The compound of formula 5 reacts with the compound of formula 8 to produce a compound of formula YY;

[0181]

[0182] In the formula, Lg is selected from the following group: halogen, substituted or unsubstituted C6-C10 aryloxy;

[0183] Wherein, the "substituted" means that one or more hydrogen atoms (1, 2, 3, 4 or 5) in the group are replaced by a group selected from the group consisting of halogen, nitro;

[0184] R is as defined above.

[0185] It should be understood that within the scope of the present invention, the above-mentioned technical features of the present invention and the technical features specifically described below (such as embodiments) can be combined with each other to form a new or preferred technical solution. Due to space limitations, they will not be described one by one here. BRIEF DESCRIPTION OF THE DRAWINGS

[0186] Figure 1 Compound 4-1 prepared in Example 5 1 H-NMR spectrum. DETAILED DESCRIPTION

[0187] After extensive and in-depth research, the inventors have provided a method for preparing C-nucleoside derivatives using heterocyclic compounds protected by N-benzyloxycarbonyl or N-tert-butyloxycarbonyl for the first time through a large number of screenings and tests. Compared with the prior art, the present invention does not need to perform temporary amino protection or heterocyclic halogenation reaction, and can directly use n-butyl lithium to remove the protons of heterocyclic compounds and perform addition with ribonucleolate. Surprisingly, the method of the present invention not only shortens the synthesis route of C-nucleoside derivatives, but also in the absence of temporary amino protection or halogen atoms as substituents, the reaction of heterocyclic compounds with ribonucleolate obtains the characteristics of simple and efficient operation and significantly improved yield; at the same time, the amino protecting group (such as Boc) is present in the second half of the synthesis route, which reduces the polarity of the compound (such as Formula 5-1 compound), and its solubility in organic solvents is better, the reaction efficiency is higher, and the intermediate purification is easier, and the product purity is higher. The present invention was completed on this basis.

[0188] the term

[0189] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.

[0190] As used herein, when used in reference to a specific recited numerical value, the term "about" means that the value may vary by no more than 1% from the recited value. For example, as used herein, the expression "about 100" includes all values ​​between 99 and 101 (e.g., 99.1, 99.2, 99.3, 99.4, etc.).

[0191] As used herein, the term "comprising" or "including (comprising)" may be open, semi-closed and closed. In other words, the term also includes "consisting essentially of" or "consisting of".

[0192] Unless otherwise indicated, the term "alkyl" by itself or as part of another substituent refers to a straight or branched hydrocarbon radical having the specified number of carbon atoms (i.e., C1-6 means 1-6 carbons), and alkyl groups may include alkyl groups of 1, 2, 3, 4, 5 or 6 carbon atoms. Examples of alkyl groups include methyl, ethyl, n-propyl, isopropyl, n-butyl, tert-butyl, isobutyl, sec-butyl, n-pentyl, n-hexyl, and the like.

[0193] Unless otherwise indicated, the term "alkenyl" refers to an unsaturated alkyl group having one or more double bonds, and the alkenyl group may include alkenyl groups of 2, 3, 4, 5, or 6 carbon atoms. Similarly, the term "alkynyl" refers to an unsaturated alkyl group having one or more triple bonds, and the alkynyl group may include alkynyl groups of 2, 3, 4, 5, or 6 carbon atoms. Examples of such unsaturated alkyl groups include vinyl, 2-propenyl, crotyl, 2-isopentenyl, 2-(butadienyl), 2,4-pentadienyl, 3-(1,4-pentadienyl), ethynyl, 1- and 3-propynyl, 3-butynyl, and higher homologs and isomers.

[0194] Unless otherwise stated, the term "halo" or "halogen" by itself or as part of another substituent refers to a fluorine, chlorine, bromine, or iodine atom. In addition, terms such as "haloalkyl" are meant to include monohaloalkyl or polyhaloalkyl. For example, the term "C1-4 haloalkyl" is meant to include trifluoromethyl, 2,2,2-trifluoroethyl, 4-chlorobutyl, 3-bromopropyl, etc.

[0195] Unless otherwise indicated, the term "aryl" means a polyunsaturated (usually aromatic) hydrocarbon radical which may be a single ring or multiple rings (up to three) fused together or linked covalently. Examples of aryl include phenyl, naphthyl.

[0196] As used herein, "inert solvent" refers to methanol, ethanol, isopropanol, chloroform, benzene, dimethyl sulfoxide, N-methylpyrrolidone, N,N-dimethylformamide, acetone, acetonitrile, acetic acid, formic acid, n-hexane, n-heptane, toluene, tetrahydrofuran, ethyl acetate, 1,4-dioxane, methyl tert-butyl ether, water or a mixture of the above solvents.

[0197] As used herein, "compound of Formula 10" and "remdesivir" are used interchangeably to refer to a compound having the structure shown in Formula 10 or a pharmaceutically acceptable salt thereof.

[0198] As used herein, Represents the junction site.

[0199] As used herein, "room temperature" refers to 4-40°C, preferably, 25±5°C.

[0200] Preparation method

[0201] The following is a more specific description of the preparation methods of the compounds of formula 2, 4, 5 and 6 of the present invention and the method for further preparing remdesivir, but these specific methods do not constitute any limitation to the present invention. Based on the teachings of the present invention, the compound of formula 6 and remdesivir can also be conveniently prepared by optionally combining the methods described in this specification with various synthetic methods known in the art, and such a combination can be easily performed by a technician in the field to which the present invention belongs.

[0202] The reaction in the method of the present invention can be carried out at any suitable temperature. For example, the reaction temperature can be about -78 ° C to about 100 ° C, or about -50 ° C to about 100 ° C, or about -25 ° C to about 50 ° C, or about -10 ° C to about 25 ° C, or about 0 ° C to about 20 ° C. In some embodiments, the reaction temperature can be about 0 ° C to about 20 ° C.

[0203] Usually, in the preparation process, each reaction is usually carried out in an inert solvent at room temperature to reflux temperature (such as 0°C to 100°C, preferably 0°C to 80°C). The reaction time is usually 0.1 hour to 60 hours, preferably 0.5 to 48 hours, such as 1, 2, 6, 12, 18, 24 or 36 hours.

[0204] The following general preparation route can be used to synthesize the compounds of Formula 2, 3, 4, 5, and 6 of the present invention and to prepare remdesivir.

[0205] The present invention provides a compound of formula M,

[0206]

[0207] In the formula,

[0208] G is selected from the following group: H or

[0209] Wherein, R is selected from the following group: tert-butyl or benzyl;

[0210] R 1 and R 2 Independently selected from the following group: H, substituted or unsubstituted C6-C10 aryl, substituted or unsubstituted benzyl, substituted or unsubstituted naphthylmethyl, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C1-C6 alkylsilyl, substituted or unsubstituted -Si(Ph)2-(C1-C6 alkyl), or two R1 together form -C(R4)2-;

[0211] R4 is independently selected from the following group: substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C2-C6 alkenyl, substituted or unsubstituted C2-C6 alkynyl, or two R4 together with the C atom to which they are attached form a substituted or unsubstituted 4-7 membered carbocyclic ring;

[0212] Here, the "substituted" means that one or more (2, 3, 4, 5) hydrogen atoms on the group are replaced by a group selected from the group consisting of halogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, or C6-C10 aryl.

[0213] In another preferred embodiment, the compound of formula M is selected from the following group:

[0214]

[0215]

[0216] In each formula, R is independently selected from the group consisting of tert-butyl or benzyl.

[0217] Preparation of compound of formula 2

[0218] In the present invention, the compound of formula 2 can be prepared by the compound of formula 1:

[0219]

[0220] Preferably, in this step, the compound of formula 1 is reacted with the compound of formula D1 to obtain the compound of formula 2

[0221]

[0222] In the formula,

[0223] Each R is independently selected from the group consisting of tert-butyl, benzyl.

[0224] Preparation of compound of formula 3

[0225]

[0226] Preferably, in this step, the compound of formula 2 is reacted with the compound of formula A to obtain the compound of formula 3.

[0227] Preferably, in this step, the reaction is carried out in the presence of an organolithium and / or organomagnesium reagent.

[0228] In another preferred embodiment, the organic lithium reagent is an alkyl lithium.

[0229] In another preferred embodiment, the organic lithium reagent is selected from the following group: methyl lithium, sec-butyl lithium, tert-butyl lithium, LDA, or a combination thereof.

[0230] In another preferred embodiment, the organomagnesium reagent is selected from the group consisting of i-PrMgCl·LiCl (Turbo Grignard reagent), s-BuMgCl·LiCl (another Turbo Grignard reagent), TMPMgCl·LiCl (Knochel HauserBase), or a combination thereof.

[0231] Preferably, the compound of formula A is

[0232] Preparation of compound of formula 4

[0233] The hydroxyl group of the compound of formula 3 undergoes a substitution reaction to obtain a compound of formula 4

[0234]

[0235] Preferably, in the step, the hydroxyl group of the compound of formula 3 is replaced by a cyano group in the presence of an acid and a cyanation agent.

[0236] In another preferred embodiment, the acid is selected from the following group: TMSOTf, trifluoromethanesulfonic acid, trifluoroacetic acid, boron trifluoride-ether complex, methanesulfonic acid or a combination thereof.

[0237] In another preferred embodiment, the cyanation agent is selected from the group consisting of TMSCN, TBSCN, ZnCN, or a combination thereof.

[0238] Preparation of compound of formula 5

[0239] The compound of formula 4 undergoes a selective deprotection reaction to obtain a compound of formula 5

[0240]

[0241] Preferably, the selective deprotection is carried out in the presence of a Lewis acid, more preferably boron trichloride.

[0242] Preparation of compound of formula 6

[0243]

[0244] Alternatively, when both R1 are H and R2 is H, the compound of formula 6 can be prepared from the compound of formula 5.

[0245]

[0246] Preferably, the compound of formula 6 can be prepared by the following method:

[0247]

[0248] Preferably, in the above formulas,

[0249] R is selected from the group consisting of tert-butyl or benzyl; and

[0250] R 1 and R 2 Independently selected from the group consisting of substituted or unsubstituted C6-C10 aryl, substituted or unsubstituted benzyl, substituted or unsubstituted naphthylmethyl, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C1-C6 alkylsilyl, or substituted or unsubstituted -Si(Ph)2-(C1-C6 alkyl);

[0251] Here, the "substituted" means that one or more (2, 3, 4, 5) hydrogen atoms on the group are replaced by a group selected from the group consisting of halogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, or C6-C10 aryl.

[0252] The present invention also provides another method for preparing a compound of formula 6 from a compound of formula 3, comprising the steps of:

[0253] (iii') a hydroxyl group of the compound of formula 3 undergoes a substitution reaction to obtain a compound of formula 4a; and

[0254]

[0255] (iv') the compound of formula 4a undergoes complete deprotection reaction to obtain a compound of formula 6;

[0256]

[0257] In the formula, R, R 1 , R 2 As defined above.

[0258] In another preferred embodiment, in formula (iii'), in an inert solvent, in the presence of an acid and a cyanation agent, the hydroxyl group of the compound of formula 3 undergoes a substitution reaction and an amino group deprotection reaction to obtain a compound of formula 4a.

[0259] In another preferred embodiment, in formula (iv'), the compound of formula 4a is subjected to a deprotection reaction in an inert solvent to obtain a compound of formula 6.

[0260] Preparation method of compound of formula 7a

[0261] The present invention provides a method for preparing a compound of formula 7a, comprising the steps of:

[0262] (a) reacting the compound of formula 5 with acetone and / or 2,2-dimethoxypropane to undergo hydroxyl protection reaction to generate a compound of formula 7a;

[0263]

[0264] wherein R is as defined above.

[0265] In another preferred embodiment, in step (a), in acetone and / or 2,2-dimethoxypropane, in the presence of a protonic acid, the compound of formula 5 undergoes a hydroxyl protection reaction with acetone and / or 2,2-dimethoxypropane to generate a compound of formula 7a.

[0266] In another preferred embodiment, the protonic acid is selected from the following group: sulfuric acid, p-toluenesulfonic acid, camphorsulfonic acid, methanesulfonic acid, trifluoromethanesulfonic acid, trifluoroacetic acid, or a combination thereof.

[0267] In another preferred embodiment, in step (a), the reaction temperature of the hydroxyl protection reaction is -40-100°C, preferably, -20 to -10°C.

[0268] Preparation method of compound of formula 7b

[0269] The present invention provides a method for preparing a compound of formula 7b, comprising the steps of:

[0270] (a) the compound of formula 5-1 undergoes a hydroxyl protection reaction with acetone and / or 2,2-dimethoxypropane and a deprotection reaction simultaneously to generate a compound of formula 7b;

[0271]

[0272] In another preferred embodiment, in step (a), in acetone and / or 2,2-dimethoxypropane, in the presence of a protonic acid, the compound of formula 5-1 undergoes a hydroxyl protection reaction with acetone and / or 2,2-dimethoxypropane to generate a compound of formula 7b.

[0273] In another preferred embodiment, the protonic acid is selected from the following group: sulfuric acid, p-toluenesulfonic acid, camphorsulfonic acid, methanesulfonic acid, trifluoromethanesulfonic acid, trifluoroacetic acid, or a combination thereof.

[0274] In another preferred embodiment, in step (a), the reaction temperature of the hydroxyl protection reaction is -40-100°C, preferably, 20-40°C.

[0275] Compound of formula 9a

[0276]

[0277] In the formula, R is selected from the following group: tert-butyl or benzyl.

[0278] Preparation method of compound of formula 9a

[0279] The present invention provides a method for preparing a compound of formula 9a, comprising the steps of:

[0280] (b) reacting the compound of formula 7a with the compound of formula 8 to obtain a compound of formula 9a;

[0281]

[0282] In the formula, Lg is selected from the following group: halogen, substituted or unsubstituted C6-C10 aryloxy;

[0283] Wherein, the "substituted" means that one or more hydrogen atoms (1, 2, 3, 4 or 5) in the group are replaced by a group selected from the following group: halogen, nitro; and

[0284] R is as defined above.

[0285] In another preferred embodiment, Lg is selected from the following group: p-nitrophenoxy, pentafluorophenoxy or chlorine.

[0286] In another preferred embodiment, in step (b), in an inert solvent, in the presence of a magnesium salt, a lithium salt and / or an aluminum salt and a base, the compound of formula 7a reacts with the compound of formula 8 to obtain a compound of formula 9a; or

[0287] In an inert solvent, in the presence of a metal organic reagent, the compound of formula 7a reacts with the compound of formula 8 to obtain a compound of formula 9a.

[0288] In another preferred embodiment, the magnesium salt is selected from the group consisting of magnesium chloride, magnesium bromide, magnesium iodide, or a combination thereof.

[0289] In another preferred embodiment, the lithium salt is selected from the following group: lithium chloride, lithium bromide, lithium iodide, or a combination thereof.

[0290] In another preferred embodiment, the aluminum salt is aluminum trichloride.

[0291] In another preferred embodiment, the base is an organic base, preferably diisopropylethylamine, triethylamine, tributylamine, N-methylmorpholine, N-methylpiperidine, pyridine, 2,6-lutidine, or a combination thereof.

[0292] In another preferred embodiment, the metal organic reagent is selected from the following group: tert-butyl magnesium chloride, isopropyl magnesium chloride, isobutyl magnesium chloride, ethyl magnesium chloride, butyl lithium, sodium hydrogen, potassium tert-butoxide, sodium tert-butoxide, sodium isopentanolate, or a combination thereof.

[0293] Compound of formula YY

[0294]

[0295] Wherein, R is selected from the following group: tert-butyl or benzyl.

[0296] Preparation method of compound of formula YY

[0297] The preparation method of the compound of formula YY comprises the steps of:

[0298] The compound of formula 5 reacts with the compound of formula 8 to produce a compound of formula YY;

[0299]

[0300] In the formula, Lg is selected from the following group: halogen, substituted or unsubstituted C6-C10 aryloxy;

[0301] Wherein, the "substituted" means that one or more hydrogen atoms (1, 2, 3, 4 or 5) in the group are replaced by a group selected from the group consisting of halogen, nitro;

[0302] R is as defined above.

[0303] Preparation of Remdesivir

[0304] The compound of formula M of the present invention can be used to prepare remdesivir or as an intermediate for preparing remdesivir.

[0305] The present invention provides a method for preparing remdesivir, comprising the steps of: using a compound of formula M as an intermediate or raw material in the preparation process of remdesivir.

[0306] Typically, the compound of formula 6 is a key intermediate of the antiviral drug remdesivir (compound of formula 10), so remdesivir can be further prepared by the method of the present invention or the novel intermediate of the present invention.

[0307] Preferably, a method for preparing remdesivir comprises the above-mentioned steps of preparing the compound of formula 6.

[0308] Preferably, a method for preparing remdesivir may further include an additional step of preparing remdesivir from the compound of formula 6.

[0309] Typically, a method for preparing remdesivir from a compound of formula 6 comprises the steps of:

[0310]

[0311] Among them, include:

[0312] The compound of formula 6 is protected with a protecting group to obtain a compound of formula 7;

[0313] Reacting the compound of formula 7 with the compound of formula 8 to obtain the compound of formula 9;

[0314] The compound of formula 9 is subjected to a deprotection reaction to obtain a compound of formula 10 (Remdesivir).

[0315] The present invention also provides a method for preparing remdesivir, comprising the steps of:

[0316] (c) deprotecting the compound of formula 9a to obtain a compound of formula 10;

[0317]

[0318] In the formula, R is selected from the following group: tert-butyl or benzyl.

[0319] In another preferred embodiment, in step (c), the hydroxyl group deprotection reaction and the amino group deprotection reaction of the compound of formula 9a can be carried out step by step in any order or simultaneously.

[0320] In another preferred embodiment, in step (c), in an inert solvent or in the absence of a solvent, in the presence of a deprotecting agent, the compound of formula 9a undergoes a deprotection reaction to obtain a compound of formula 10. In another preferred embodiment, the deprotecting agent is selected from the group consisting of sulfuric acid, hydrochloric acid, formic acid, acetic acid, p-toluenesulfonic acid, camphorsulfonic acid, methanesulfonic acid, trifluoroacetic acid, and trifluoromethanesulfonic acid.

[0321] In another preferred embodiment, in step (c), the deprotection temperature is -20-50°C, preferably, -10-30°C.

[0322] In another preferred embodiment, before step (c), the method further comprises the following steps:

[0323] (b) reacting the compound of formula 7a with the compound of formula 8 to obtain a compound of formula 9a;

[0324]

[0325] In the formula, Lg is selected from the following group: halogen, substituted or unsubstituted C6-C10 aryloxy;

[0326] Wherein, the "substituted" means that one or more hydrogen atoms (1, 2, 3, 4 or 5) in the group are replaced by a group selected from the group consisting of halogen, nitro;

[0327] R is as defined above.

[0328] In another preferred embodiment, in step (b), in an inert solvent, in the presence of a magnesium salt, a lithium salt and / or an aluminum salt and a base, the compound of formula 7a reacts with the compound of formula 8 to obtain a compound of formula 9a; or

[0329] In an inert solvent, in the presence of a metal organic reagent, the compound of formula 7a reacts with the compound of formula 8 to obtain a compound of formula 9a.

[0330] In another preferred embodiment, before step (b), the method further comprises the following steps:

[0331] (a) reacting the compound of formula 5 with acetone and / or 2,2-dimethoxypropane to undergo hydroxyl protection reaction to generate a compound of formula 7a;

[0332]

[0333] Wherein, R is as defined above.

[0334] In another preferred embodiment, in step (a), in acetone and / or 2,2-dimethoxypropane, in the presence of a protonic acid, the compound of formula 5 undergoes a hydroxyl protection reaction with acetone and / or 2,2-dimethoxypropane to generate a compound of formula 7a.

[0335] Preferably, the method for preparing remdesivir of the present invention comprises the following steps:

[0336]

[0337] Wherein, R and Lg are as defined above.

[0338] The present invention also provides a method for preparing remdesivir, comprising the steps of:

[0339] (z) the compound of formula YY undergoes a deprotection reaction to generate a compound of formula 10;

[0340]

[0341] In the formula, R is selected from the following group: tert-butyl or benzyl.

[0342] In another preferred embodiment, in step (z), the compound of formula YY undergoes a deprotection reaction in an inert solvent in the presence of a deprotecting agent to generate a compound of formula 10.

[0343] In another preferred embodiment, in step (z), the inert solvent is an alcohol, preferably, a C1-C6 alkyl alcohol, more preferably, methanol, ethanol, isopropanol, or a combination thereof.

[0344] In another preferred embodiment, the deprotecting agent is a protonic acid. Preferably, the protonic acid is selected from the following group: sulfuric acid, p-toluenesulfonic acid, camphorsulfonic acid, methanesulfonic acid, trifluoromethanesulfonic acid, trifluoroacetic acid, or a combination thereof.

[0345] In another preferred embodiment, before step (z), the method further comprises the following steps:

[0346] (y) reacting a compound of formula 5 with a compound of formula 8 to produce a compound of formula YY;

[0347]

[0348] In the formula, Lg is selected from the following group: halogen, substituted or unsubstituted C6-C10 aryloxy;

[0349] Wherein, the "substituted" means that one or more hydrogen atoms (1, 2, 3, 4 or 5) in the group are replaced by a group selected from the group consisting of halogen, nitro;

[0350] R is as defined above.

[0351] In another preferred embodiment, in step (y), in an inert solvent, in the presence of a magnesium salt, a lithium salt and / or an aluminum salt and a base, the compound of formula 5 reacts with the compound of formula 8 to obtain a compound of formula YY; or

[0352] In an inert solvent, in the presence of a metal organic reagent, the compound of formula 5 reacts with the compound of formula 8 to obtain a compound of formula YY.

[0353] Preferably, the method for preparing remdesivir of the present invention comprises the following steps:

[0354]

[0355] Wherein, R and Lg are as defined above.

[0356] In another preferred embodiment, R is tert-butyl.

[0357] Surprisingly, when the amino groups in compounds 5, 7a, 9a and YY are protected by tert-butyloxycarbonyl (Boc) or benzyloxycarbonyl (Cbz), the compounds have lower polarity, making the product easy to purify, and significantly improving the yield and purity of the product. For example, when the R group of compound 5 is a Boc group, the solubility in organic solvents is better, so the reaction yield with the compound of formula 8 is significantly improved.

[0358] Remdesivir can also be prepared from the compound of formula 7b via 9b.

[0359]

[0360] The main advantages of the present invention include:

[0361] (a) The present invention synthesizes compound 6 from compound 2 which is easy to prepare and has low cost, thus having low cost and avoiding the use of expensive halide raw materials;

[0362] (b) The present invention avoids the temporary amino protection required when using the halogenated compound 2 to add the ribolactone A, so the repeatability of the reaction is significantly improved;

[0363] (c) the yield of the method of the present invention is high;

[0364] (d) The stereoselectivity of the method of the present invention is good;

[0365] (e) The present invention has the advantages of being easy to industrialize and produce;

[0366] (f) When the amino group of compound 5 has a Boc or Cbz protecting group, the solubility in organic solvents is better, so the reaction yield with the compound of formula 8 is significantly improved.

[0367] (g) In the method for preparing remdesivir of the present invention, the intermediate is easy to purify, and the yield and purity of the product are significantly improved.

[0368] The present invention will be further described below in conjunction with specific implementation. It should be understood that these embodiments are only used to illustrate the present invention and are not intended to limit the scope of the present invention. The experimental methods in the following examples without specifying specific conditions are usually based on conventional conditions or the conditions recommended by the manufacturer. Unless otherwise stated, percentages and parts are calculated by weight.

[0369] abbreviation:

[0370] TLC is thin layer chromatography;

[0371] EtOAc is ethyl acetate;

[0372] THF is tetrahydrofuran;

[0373] TBME is tert-butyl methyl ether;

[0374] Boc2O is di-tert-butyl dicarbonate;

[0375] Cbz2O is benzyloxycarbonic anhydride;

[0376] CbzCl is benzyl chloroformate;

[0377] LC-MS was measured on an Agilent 1260 Infinity II + Infinity Lab LC / MSD. TLC was checked under a WFH-203B UV lamp. High-resolution mass spectrometry was measured on a Waters, Q-Tof Ultima Global spectrometer. NMR was measured on a Bruker 400M NMR spectrometer.

[0378] Liquid chromatography was measured on Agilent 1260 Infinity II, Thermo U3000, or Shimadzu LC-16 instruments. The liquid chromatography method was:

[0379] Chromatographic column: Welch CN (250mm×4.6mm×5um)

[0380] Mobile phase: A - 0.1% phosphoric acid in water; B - 0.1% phosphoric acid in acetonitrile.

[0381] Flow rate: 1.0ml / min.

[0382] Column temperature: 40℃.

[0383] Detection wavelength: 210nm.

[0384] Injection volume: 1 μl.

[0385] Analysis time: 40min

[0386] Gradient Program:

[0387]

[0388] or:

[0389] Chromatographic column: Welch C18 (250 mm × 4.6 mm × 5 um).

[0390] Mobile phase: A—0.1% phosphoric acid in water; B—0.1% phosphoric acid in methanol.

[0391] Flow rate: 1.0ml / min.

[0392] Column temperature: 40℃.

[0393] Detection wavelength: 240nm.

[0394] Injection volume: 1 μl.

[0395] Analysis time: 40min

[0396] Gradient Program:

[0397]

[0398] Example 1 Preparation of Compound 2-1

[0399]

[0400] 1.34 g of pyrrolo[2,1-f][1,2,4]triazine-4-amine (compound 1), 20 mL of tetrahydrofuran and 20 mL of saturated sodium bicarbonate aqueous solution were added to the reaction flask, and 3.27 g of Boc2O was added in batches. The mixture was reacted at 20-25°C for 16 hours, 50 mL of water was added, and the mixture was extracted with ethyl acetate (20 mL×2). The organic phases were combined, washed with saturated brine (30 mL×3), dried over anhydrous sodium sulfate, concentrated, and separated on a silica gel column (10:1, V / V, petroleum ether: ethyl acetate) to obtain 2.13 g of a white solid product 2-1, with a yield of 91%. HRMS (ESI+): C11H13N4NaO2+, MW256.0935.

[0401] Example 2 Preparation of Compound 2-2

[0402]

[0403] Compound 1 (1.2 mmol), DMF (10 mL) and triethylamine (2.0 mmol) were added to the reaction flask, benzyloxycarbonyl chloride (2.0 mmol) was added dropwise, and the mixture was reacted at 40-25°C for 16 hours, 50 mL of water was added, and the mixture was extracted with ethyl acetate (20 mL×2), the organic phases were combined, washed with saturated brine (30 mL×3), dried over anhydrous sodium sulfate, concentrated, and separated by column chromatography to obtain a white solid product 2-2 (0.5 mmol). HRMS (ESI+): C14H11N4NaO2+, MW290.0776.

[0404] Example 3 Preparation of Compound 3-1

[0405]

[0406] Compound 2-1 (1.0 mmol) was dissolved in THF (7 mL), cooled to -50 to -70 °C, and n-butyl lithium (2.5 M hexane solution, 2.2 mmol) was added dropwise. After the addition, the mixture was stirred at -60 °C for 2 h. A solution of 2,3,5-tribenzyloxy-D-ribonic acid-1,4-lactone (1.1 mmol) in THF (10 mL) was added to the mixture, and the mixture was stirred at -50 °C for 5 h. The reaction solution was then washed with water, saturated sodium bicarbonate aqueous solution, and saturated brine in sequence. Finally, the obtained organic phase was concentrated and column chromatography was performed to obtain product 3-1 (0.69 mmol), HRMS (ESI+): C37H40N4NaO7+, MW675.2799.

[0407] Example 3.1 Preparation of Compound 3-1

[0408] Compound 2-1 (1.0 mmol) was dissolved in THF (7 mL), cooled to -50 to -70°C, and n-butyl lithium (2.5 M hexane solution, 2.2 mmol) was added dropwise. After the addition, the mixture was stirred at -60°C for 2 h.

[0409] Prepare another reaction bottle, add 2,3,5-tribenzyloxy-D-ribonic acid-1,4-lactone (1.1mmol), THF (10mL), neodymium trichloride (1.1mmol) and anhydrous tetrabutylammonium chloride (1.1mmol), stir at room temperature for 5h, precool the reaction solution to -60°C, and add the above-mentioned lithium mixture to the reaction solution. Continue to stir the mixture at -50°C for 3h, gradually heat to -20°C, add acetic acid (3mmol) to quench the reaction, and then wash the reaction solution with water, saturated sodium bicarbonate aqueous solution, and saturated brine in turn. Finally, the obtained organic phase is concentrated and column chromatography is performed to obtain product 3-1 (0.65mmol), and the HRMS analysis results are consistent with the compound 3-1 sample obtained in Example 3.

[0410] Example 3.2 Preparation of Compound 3-1

[0411] Compound 2-1 (1.0 mmol) was dissolved in THF (7 mL), cooled to -50 to -70°C, isopropylamine (0.01 mmol) was added dropwise first, and then n-butyl lithium (2.5 M hexane solution, 2.2 mmol) was added dropwise, and after completion of the addition, the mixture was stirred at -60°C for 2 h.

[0412] Prepare another reaction bottle, add 2,3,5-tribenzyloxy-D-ribonic acid-1,4-lactone (1.1mmol), THF (10mL), neodymium trichloride (1.1mmol) and anhydrous tetrabutylammonium chloride (1.1mmol), stir at room temperature for 5h, precool the reaction solution to -60°C, and add the above-mentioned lithium mixture to the reaction solution. Continue to stir the mixture at -50°C for 3h, gradually heat to -20°C, add acetic acid (3mmol) to quench the reaction, and then wash the reaction solution with water, saturated sodium bicarbonate aqueous solution, and saturated brine in turn. Finally, the obtained organic phase is concentrated and column chromatography is performed to obtain product 3-1 (0.66mmol), and the HRMS analysis results are consistent with the compound 3-1 sample obtained in Example 3.

[0413] Example 4 Preparation of Compound 3-2

[0414]

[0415] Compound 2-2 (1.0 mmol) was dissolved in THF (7 mL), cooled to -50 to -70°C, isopropylamine (0.01 mmol) was added dropwise, and then n-butyllithium (2.5 M hexane solution, 2.2 mmol) was added dropwise. After the addition, the mixture was stirred at -60°C for 2 h.

[0416] Prepare another reaction bottle, add 2,3,5-tribenzyloxy-D-ribonic acid-1,4-lactone (1.1mmol), THF (10mL), neodymium trichloride (1.1mmol) and anhydrous tetrabutylammonium chloride (1.1mmol), stir at room temperature for 5h, precool the reaction solution to -60℃, and add the above lithium mixture to the reaction solution. Continue to stir the mixture at -50℃ for 3h, gradually heat to -20℃, add acetic acid (3mmol) to quench the reaction, and then wash the reaction solution with water, saturated sodium bicarbonate aqueous solution, and saturated brine in turn. Finally, the obtained organic phase is concentrated and column chromatography is performed to obtain product 3-2 (0.41mmol), HRMS (ESI+): C40H38N4NaO7+, MW709.2639.

[0417] Example 5 Preparation of Compound 4-1

[0418]

[0419] The solution of compound 3-1 (2.3 mmol) in DCM (50 mL) was cooled to -40°C, trifluoroacetic acid (6 mmol) was added, and then a mixed solution of TMSOTf (10 mmol) and TMSCN (10 mmol) in DCM (20 mL) precooled to -40°C was added, and then the mixture was stirred at -30°C for 30 min and terminated by adding a KOH aqueous solution precooled to -10°C. After the mixture was separated, the organic phase was washed with saturated brine and concentrated. Finally, the obtained organic phase was concentrated and column chromatography was performed to obtain the product 4-1 (2.0 mmol), HRMS (ESI+): C38H39N5NaO6+, MW684.2810. NMR spectrum Figure 1 shown.

[0420] Example 6 Preparation of Compound 4-1

[0421]

[0422] A method similar to that in Example 5 was used, except that Zn(CN)2 was used instead of TMSCN.

[0423] A suspension of compound 3-1 (2.3 mmol) and Zn(CN)2 (1.5 mmol) in DCM (50 mL) was cooled to -40°C, trifluoroacetic acid (6 mmol) was added, and then TMSOTf (10 mmol) was added. The mixture was then stirred at -30°C for 30 min and terminated by adding saturated sodium acetate aqueous solution. After the mixture was separated, the organic phase was washed with saturated brine and concentrated. Finally, the obtained organic phase was concentrated and column chromatography was performed to obtain product 4-1 (0.21 mmol). The HRMS analysis results were consistent with the compound 4-1 sample obtained in Example 5.

[0424] Example 7 Preparation of Compound 4-2

[0425]

[0426] A solution of compound 3-2 (2.5 mmol) in DCM (50 mL) was cooled to -40°C, trifluoroacetic acid (6 mmol) was added, and then a mixed solution of TMSOTf (10 mmol) and TMSCN (10 mmol) in DCM (20 mL) precooled to -40°C was added, and then the mixture was stirred at -30°C for 30 min and terminated by adding a KOH aqueous solution precooled to -10°C. After the mixture was separated, the organic phase was washed with saturated brine and concentrated. Finally, the obtained organic phase was concentrated and column chromatography was performed to obtain product 4-2 (2.1 mmol), HRMS (ESI+): C41H37N5NaO6+, MW718.2645.

[0427] Example 8 Preparation of Compound 4-2

[0428]

[0429] A method similar to that in Example 7 was used, except that Zn(CN)2 was used instead of TMSCN.

[0430] Example 9 Preparation of Compound 4a-1

[0431]

[0432] A solution of compound 3-1 (2.3 mmol) in DCM (50 mL) was cooled to -40°C, trifluoromethanesulfonic acid (6 mmol) was added, and then a mixed solution of TMSOTf (10 mmol) and TMSCN (10 mmol) in DCM (20 mL) precooled to -40°C was added, and then the mixture was stirred at -30°C for 30 min and terminated by adding a KOH aqueous solution precooled to -10°C. After the mixture was separated, the organic phase was washed with saturated brine and concentrated. Finally, the obtained organic phase was concentrated and column chromatography was performed to obtain product 4a-1 (2.1 mmol), HRMS (ESI+): C33H31N5NaO4+, MW584.2272.

[0433] Example 10 Preparation of Compound 5-1

[0434]

[0435] Compound 4-1 (1 mmol) was dissolved in DCM (5 mL) and cooled to -60 °C. Boron trichloride (1 M DCM solution, 3.4 mmol) was added and stirring was continued at -60 °C for 3 h. Methanol (30 mL) was then added and the mixture was concentrated below -10 degrees until no solvent flowed out. Methanol (30 mL) was then added and concentrated until no solvent flowed out. A 20% aqueous potassium carbonate solution was then added to the mixture and the mixture was gradually heated to room temperature. The solid precipitated, filtered, washed with water, and dried to give the product 5-1 (0.85 mmol), HRMS (ESI+): C17H21N5NaO6+, MW414.1389.

[0436] Example 11 Preparation of Compound 6

[0437]

[0438] Compound 5-1 (1 mmol) was dissolved in 2 mL of HCl-isopropanol solution (1 M), stirred at room temperature for 1 h, and filtered to obtain the hydrochloride salt of product 6 (0.95 mmol), HRMS (ESI+): C12H14N5O4+, MW292.1048.

[0439] Example 12 Preparation of Compound 6

[0440]

[0441] Compound 4-1 (1 mmol) was dissolved in DCM (5 mL) and cooled to -20 °C. Boron trichloride (1 M DCM solution, 4 mmol) was added and stirring was continued at -20 °C for 3 h. Methanol (30 mL) was then added and the mixture was concentrated below -10 degrees until no solvent flowed out. Methanol (30 mL) was then added and concentrated until no solvent flowed out. A potassium carbonate aqueous solution (20%) was then added to the mixture and the mixture was gradually heated to room temperature. The solid precipitated, filtered, washed with water, and dried to obtain product 6 (0.91 mmol). The HRMS analysis results were consistent with the compound 6 sample obtained in Example 11.

[0442] Example 13 Preparation of Compound 6

[0443]

[0444] Compound 4-2 (1 mmol) was dissolved in DCM (5 mL) and cooled to -20 °C. Boron trichloride (1 M DCM solution, 4 mmol) was added and stirring continued at -20 °C for 3 h. Then stirring was continued at -10 °C for 3 h. Methanol (30 mL) was then added. The mixture was concentrated below -10 degrees until no solvent flowed out. Methanol (30 mL) was then added and concentrated until no solvent flowed out. Then an aqueous potassium carbonate solution (20%) was added to the mixture and the mixture was gradually heated to room temperature. The solid precipitated, filtered, washed with water, and dried to obtain product 6 (0.65 mmol). The HRMS analysis results were consistent with the compound 6 sample obtained in Example 11.

[0445] Example 14 Preparation of Compound 5-2

[0446]

[0447] Compound 4-2 (1 mmol) was dissolved in DCM (5 mL) and cooled to -60 °C. Boron trichloride (1 M DCM solution, 3.4 mmol) was added and stirring was continued at -60 °C for 3 h. Methanol (30 mL) was then added and the mixture was concentrated below -10 degrees until no solvent flowed out. Methanol (30 mL) was then added and concentrated until no solvent flowed out. A potassium carbonate aqueous solution (20%) was then added to the mixture and the mixture was gradually heated to room temperature. The solid precipitated, filtered, washed with water, and dried to give the product 5-2 (0.85 mmol), HRMS (ESI+): C20H20N5O6+, MW426.1415.

[0448] Example 15 Preparation of Compound 7a-1

[0449]

[0450] Compound 5-1 (2 mmol) was dissolved in acetone (10 mL) and 2,2-dimethoxypropane (5 mL), and the pH was adjusted to 1 with anhydrous p-toluenesulfonic acid, and stirred at -10 to -20°C for 2 h. Sodium bicarbonate was added to adjust the pH of the reaction system to above 7, and the reaction mixture was concentrated to dryness. The residue was subjected to column chromatography to obtain 7a-1 (1.84 mmol). HRMS (ESI+): C20H25N5NaO6+, MW454.1704.

[0451] Example 15.1 Preparation of Compound 7b

[0452]

[0453] Compound 5-1 (2 mmol) was dissolved in acetone (10 mL) and 2,2-dimethoxypropane (5 mL), and the pH was adjusted to 1 with anhydrous p-toluenesulfonic acid, and stirred at 20-30°C for 2 h. Sodium bicarbonate was added to adjust the pH of the reaction system to above 7, and the reaction mixture was concentrated to dryness. The residue was subjected to column chromatography to obtain 7b (1.9 mmol). HRMS (ESI+): C15H17N5NaO4+, MW354.1178.

[0454] Example 16 Preparation of Compound 7a-2

[0455]

[0456] Compound 5-1 (2 mmol) was dissolved in acetone (10 mL) and 2,2-dimethoxypropane (5 mL), and the pH was adjusted to 1 with anhydrous p-toluenesulfonic acid, and stirred at room temperature for 2 h. Sodium bicarbonate was added to adjust the pH of the reaction system to above 7, and the reaction mixture was concentrated to dryness. The residue was subjected to column chromatography to obtain 7a-2 (1.9 mmol). HRMS (ESI+): C23H23N5NaO6+, MW488.1549.

[0457] Example 17 Preparation of Compound 9a-1

[0458]

[0459] Compound 7a-1 (2 mmol), compound 8 (2.1 mmol), and magnesium chloride (2.3 mmol) were suspended in anhydrous acetonitrile (30 mL), and DIPEA (4 mmol) was added dropwise. The mixture was stirred at 0-10°C for 3 h, and then 2-methyltetrahydrofuran (20 mL) and water (20 mL) were added. The liquids were separated, and the organic phase was washed with citric acid aqueous solution, potassium carbonate aqueous solution and water in sequence. The organic phase was concentrated to dryness, and the residue was subjected to column chromatography to obtain 9a-1 (light yellow oil, 1.8 mmol). HRMS (ESI+): C35H47N6NaO10P+, MW765.2990.

[0460] Example 17.1 Preparation of Compound 9b

[0461]

[0462] Compound 7b (2 mmol), compound 8 (2.1 mmol), and magnesium chloride (2.3 mmol) were suspended in anhydrous acetonitrile (30 mL), and DIPEA (4 mmol) was added dropwise. The mixture was stirred at 0-10°C for 3 h, and then 2-methyltetrahydrofuran (20 mL) and water (20 mL) were added. The liquids were separated, and the organic phase was washed with citric acid aqueous solution, potassium carbonate aqueous solution and water in sequence. The organic phase was concentrated to dryness, and the residue was subjected to column chromatography to obtain 9b (1.6 mmol). HRMS (ESI+): C30H39N6NaO8P+, MW665.2462.

[0463] Example 18 Preparation of Compound 9a-2

[0464]

[0465] Compound 7a-2 (2 mmol), compound 8 (2.1 mmol), and magnesium chloride (2.3 mmol) were suspended in anhydrous acetonitrile (40 mL), and DIPEA (4 mmol) was added dropwise. The mixture was stirred at 0-10°C for 3 h, and then 2-methyltetrahydrofuran (30 mL) and water (30 mL) were added. The liquids were separated, and the organic phase was washed with citric acid aqueous solution, potassium carbonate aqueous solution and water in sequence. The organic phase was concentrated to dryness, and the residue was subjected to column chromatography to obtain 9a-2 (colorless oil, 1.8 mmol). HRMS (ESI+): C38H45N6NaO10P+, MW799.2832.

[0466] Example 19 Preparation of Compound 9a-2

[0467]

[0468] Compound 7a-2 (2 mmol), compound 8 (2.1 mmol), and magnesium chloride (2.3 mmol) were suspended in anhydrous acetonitrile (40 mL), and DIPEA (4 mmol) was added dropwise. The mixture was stirred at 0-10 ° C for 3 h, and then 2-methyltetrahydrofuran (10 mL) and water (10 mL) were added. The liquid was separated, and the organic phase was washed with citric acid aqueous solution, potassium carbonate aqueous solution and water in turn. The organic phase was concentrated to dryness, and the residue was subjected to column chromatography to obtain 9a-2 (colorless oil, 1.6 mmol). The analytical data was consistent with the 9a-2 standard sample. The HRMS analysis results were consistent with the compound 9a-2 sample obtained in Example 18.

[0469] Example 20 Preparation of Remdesivir

[0470]

[0471] Compound 9b (1 mmol) was dissolved in acetonitrile (20 mL), concentrated hydrochloric acid (5 mL) was added at 0°C, and stirred at 0-10°C for 2 h, followed by addition of 2-methyltetrahydrofuran (30 mL) and water (30 mL), separation, and the organic phase was washed with potassium carbonate aqueous solution and water in turn, and the organic phase was concentrated to dryness, and the residue was subjected to column chromatography to obtain remdesivir 10 (0.8 mmol). HRMS (ESI+): C27H35N6NaO8P+, MW625.2153.

[0472] Example 21 Preparation of Remdesivir

[0473]

[0474] Compound 9a-1 (1 mmol) was dissolved in acetonitrile (20 mL), concentrated hydrochloric acid (5 mL) was added at 0°C, and stirred at 0-10°C for 2 h, followed by addition of 2-methyltetrahydrofuran (30 mL) and water (30 mL), separation, and the organic phase was washed with potassium carbonate aqueous solution and water in turn, and the organic phase was concentrated to dryness, and the residue was subjected to column chromatography to obtain remdesivir 10 (0.8 mmol). HRMS (ESI+): C27H35N6NaO8P+, MW625.2153.

[0475] Example 22 Preparation of Remdesivir

[0476]

[0477] Compound 9a-2 (1 mmol) was dissolved in acetonitrile (20 mL), concentrated hydrochloric acid (5 mL) was added at 0 ° C, and stirred at room temperature for 2 h, followed by addition of 2-methyltetrahydrofuran (30 mL) and water (30 mL), separation, and the organic phase was washed with potassium carbonate aqueous solution and water in turn, and the organic phase was concentrated to dryness, and the residue was subjected to column chromatography to obtain remdesivir 10 (0.2 mmol). The HRMS analysis results were consistent with the compound 10 sample obtained in Example 21.

[0478] Example 23 Preparation of Compound YY

[0479]

[0480] Compound 5-1 (1 mmol), compound 8 (1.1 mmol), and magnesium chloride (1.2 mmol) were suspended in anhydrous acetonitrile (20 mL), and DIPEA (2 mmol) was added dropwise. The mixture was stirred at 0-10°C for 3 h, and then 2-methyltetrahydrofuran (10 mL) and water (10 mL) were added. The liquids were separated, and the organic phase was washed with citric acid aqueous solution, potassium carbonate aqueous solution and water in sequence. The organic phase was concentrated to dryness, and the residue was subjected to column chromatography to obtain YY (0.7 mmol). HRMS (ESI+): C32H43N6NaO10P+, MW725.2677.

[0481] Example 24 Preparation of Compound YY

[0482]

[0483] Compound 5-1 (1 mmol), compound 9 (1.1 mmol), magnesium chloride (1.2 mmol) were suspended in anhydrous acetonitrile (20 mL), DIPEA (2 mmol) was added dropwise, the mixture was stirred at 0-10 ° C for 3 h, then 2-methyltetrahydrofuran (10 mL) and water (10 mL) were added, the liquid was separated, the organic phase was washed with citric acid aqueous solution, potassium carbonate aqueous solution and water in turn, the organic phase was concentrated to dryness, and the residue was subjected to column chromatography to obtain YY (0.8 mmol). The HRMS analysis results were consistent with the compound YY sample obtained in Example 23.

[0484] Example 25 Preparation of Remdesivir

[0485]

[0486] Compound YY (1 mmol) was dissolved in acetonitrile (20 mL), concentrated hydrochloric acid (5 mL) was added at 0°C, stirred at 0-10°C for 2 h, then 2-methyltetrahydrofuran (30 mL) and water (30 mL) were added, the liquids were separated, the organic phase was washed with potassium carbonate aqueous solution and water in turn, the organic phase was concentrated to dryness, and the residue was subjected to column chromatography to obtain 10 (0.9 mmol). The HRMS analysis results were consistent with the sample of compound 10 obtained in Example 21.

[0487] Example 26 Preparation of Compound YY

[0488]

[0489] Compound 5-2 (1 mmol), compound 8 (1.1 mmol), and magnesium chloride (1.2 mmol) were suspended in anhydrous acetonitrile (20 mL), and DIPEA (2 mmol) was added dropwise. The mixture was stirred at 0-10°C for 3 h, and then 2-methyltetrahydrofuran (10 mL) and water (10 mL) were added. The liquids were separated, and the organic phase was washed with citric acid aqueous solution, potassium carbonate aqueous solution and water in sequence. The organic phase was concentrated to dryness, and the residue was subjected to column chromatography to obtain YYa (0.8 mmol). HRMS (ESI+): C35H41N6NaO10P+, MW759.2516.

[0490] Example 27 Preparation of Remdesivir

[0491]

[0492] Compound YYa (1 mmol) was dissolved in acetonitrile (20 mL), concentrated hydrochloric acid (5 mL) was added at 0°C, stirred at room temperature for 2 h, then 2-methyltetrahydrofuran (30 mL) and water (30 mL) were added, the liquids were separated, the organic phase was washed with potassium carbonate aqueous solution and water in turn, the organic phase was concentrated to dryness, and the residue was subjected to column chromatography to obtain 10 (0.3 mmol). The HRMS analysis results were consistent with the sample of compound 10 obtained in Example 21.

[0493] The results show that, compared with the prior art, in the method of the present invention, only N protection is performed on heterocyclic compounds without halogenation (bromination or iodination), without the need for temporary amino protection, and then organic lithium or organic magnesium is directly used to remove protons, and addition is performed with ribonolactone, which not only shortens the route but also improves the yield. The inventor unexpectedly found that when the amino group of the compound of formula 5 has a Boc or Cbz protecting group, the compound of formula 5 has good solubility in an organic solvent and can directly react with a phosphamide (compound of formula 8) to obtain structure YY, thereby avoiding the additional step of using acetone protection. And when the amino group of the compound of formula 5 has a Boc or Cbz protecting group, each intermediate is easy to purify, and the yield and purity of the product are significantly improved.

[0494] All documents mentioned in the present invention are cited as references in this application, just as each document is cited as reference individually. In addition, it should be understood that after reading the above teachings of the present invention, those skilled in the art can make various changes or modifications to the present invention, and these equivalent forms also fall within the scope defined by the claims attached to this application.

Claims

1. A method for preparing a compound of formula 6, characterized in that: Includes steps: (i) subjecting the amino group of the compound of formula 1 to an amino protection reaction to obtain a compound of formula 2; (ii) reacting the compound of formula 2 with the compound of formula A to obtain a compound of formula 3; Then, step (iii) or (iii') is performed, wherein (iii) the hydroxyl group of the compound of formula 3 undergoes a substitution reaction to obtain a compound of formula 4; (iii') the hydroxyl group of the compound of formula 3 undergoes a substitution reaction to obtain a compound of formula 4a; and step (iv) or (iv'), wherein (iv) the compound of formula 4 undergoes a complete deprotection reaction to obtain a compound of formula 6; (iv') the compound of formula 4a undergoes complete deprotection reaction to obtain a compound of formula 6; In the above formulas, R is selected from the group consisting of tert-butyl or benzyl; and R 1 and R 2 Independently selected from the group consisting of substituted or unsubstituted benzyl, substituted or unsubstituted naphthylmethyl, substituted or unsubstituted C1-C6 alkylsilyl, or substituted or unsubstituted -Si(Ph)2-(C1-C6 alkyl); Here, the "substituted" means that one or more hydrogen atoms on the group are replaced by a group selected from the group consisting of halogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, or C6-C10 aryl.

2. The method according to claim 1, characterized in that The method has one or more of the following steps: (i) in an inert solvent, subjecting the amino group of the compound of formula 1 to an amino protection reaction to obtain a compound of formula 2; (ii) reacting the compound of formula 2 with the compound of formula A in an inert solvent in the presence of an organolithium and / or organomagnesium reagent to obtain a compound of formula 3; wherein the organolithium reagent is selected from the group consisting of methyl lithium, sec-butyl lithium, tert-butyl lithium, LDA, or a combination thereof; and the organomagnesium reagent is selected from the group consisting of i-PrMgCl·LiCl, s-BuMgCl·LiCl, TMPMgCl·LiCl, or a combination thereof; (iii) in an inert solvent, in the presence of an acid and a cyanating agent, the hydroxyl group of the compound of formula 3 undergoes a substitution reaction to obtain a compound of formula 4; or (iii') in an inert solvent, in the presence of an acid and a cyanating agent, the hydroxyl group of the compound of formula 3 undergoes a substitution reaction and an amino group deprotection reaction to obtain a compound of formula 4a; in step (iii) or (iii'), the acid is independently selected from the group consisting of TMSOTf, trifluoromethanesulfonic acid, trifluoroacetic acid, boron trifluoride-ether complex, methanesulfonic acid; and the cyanating agent is independently selected from the group consisting of TMSCN, TBSCN, ZnCN, or a combination thereof; and / or (iv) subjecting the compound of formula 4 to a deprotection reaction in an inert solvent to obtain a compound of formula 6; or (iv') subjecting the compound of formula 4a to a deprotection reaction in an inert solvent to obtain a compound of formula 6.

3. A method for preparing a compound of formula 6, characterized in that: Includes steps: (i) subjecting the amino group of the compound of formula 1 to an amino protection reaction to obtain a compound of formula 2; (ii) reacting the compound of formula 2 with the compound of formula A to obtain a compound of formula 3; (iii) the hydroxyl group of the compound of formula 3 undergoes a substitution reaction to obtain a compound of formula 4; (iv) selectively deprotecting the compound of formula 4 to obtain a compound of formula 5; and (v) deprotecting the compound of formula 5 to obtain a compound of formula 6; and In the above formulas, R is selected from the group consisting of tert-butyl or benzyl; and R 1 and R 2 Independently selected from the group consisting of substituted or unsubstituted benzyl, substituted or unsubstituted naphthylmethyl, substituted or unsubstituted C1-C6 alkylsilyl, or substituted or unsubstituted -Si(Ph)2-(C1-C6 alkyl); Here, the "substituted" means that one or more hydrogen atoms on the group are replaced by a group selected from the group consisting of halogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, or C6-C10 aryl.

4. The method according to claim 3, characterized in that The method has one or more of the following steps: (i) in an inert solvent, subjecting the amino group of the compound of formula 1 to an amino protection reaction to obtain a compound of formula 2; (ii) reacting the compound of formula 2 with the compound of formula A in an inert solvent in the presence of an organolithium and / or an organomagnesium to obtain a compound of formula 3; wherein the organolithium reagent is selected from the group consisting of methyl lithium, sec-butyl lithium, tert-butyl lithium, LDA, or a combination thereof; and the organomagnesium reagent is selected from the group consisting of i-PrMgCl·LiCl, s-BuMgCl·LiCl, TMPMgCl·LiCl, or a combination thereof; (iii) in an inert solvent, in the presence of an acid and a cyanation agent, a hydroxyl group of the compound of formula 3 undergoes a substitution reaction to obtain a compound of formula 4; the acid is independently selected from the group consisting of TMSOTf, trifluoromethanesulfonic acid, trifluoroacetic acid, boron trifluoride-ether complex, and methanesulfonic acid; and the cyanation agent is independently selected from the group consisting of TMSCN, TBSCN, ZnCN, or a combination thereof (iv) in an inert solvent, in the presence of boron trichloride, subjecting the compound of formula 4 to a selective deprotection reaction to obtain a compound of formula 5; and / or (v) In an inert solvent, in the presence of a Lewis acid or a protonic acid, the compound of formula 5 undergoes a deprotection reaction to obtain a compound of formula 6.

5. The preparation method according to any one of claims 1 to 4, characterized in that: R 1 and R 2 Independently selected from the group consisting of 2-naphthylmethyl, 1-naphthylmethyl, tert-butyldimethylsilyl, tert-butyldiphenylsilyl, triisopropylsilyl, triethylsilyl, benzyl, p-methoxybenzyl, benzyl substituted with halogen or C1-C6 linear or branched alkyl.

6. A method for preparing remdesivir, characterized in that: The method comprises the steps of preparing compound 6 as described in any one of claims 1-5.

7. A compound of formula M, In the formula, G is selected from the following group: H or in, R is selected from the group consisting of tert-butyl or benzyl; R 1 and R 2 Independently selected from the group consisting of substituted or unsubstituted benzyl, substituted or unsubstituted naphthylmethyl, substituted or unsubstituted C1-C6 alkylsilyl, substituted or unsubstituted -Si(Ph)2-(C1-C6 alkyl), or two R1 together form -C(R4)2-; R4 is independently selected from the following group: substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C2-C6 alkenyl, substituted or unsubstituted C2-C6 alkynyl, or two R4 together with the C atom to which they are attached form a substituted or unsubstituted 4-7 membered carbocyclic ring; Wherein, the "substituted" means that one or more hydrogen atoms on the group are replaced by a group selected from the group consisting of halogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, or C6-C10 aryl; and The compound of formula M is not 8. The compound of formula M according to claim 7, characterized in that The compound is selected from the group consisting of: wherein R is independently selected from the group consisting of tert-butyl or benzyl; and R 1 and R 2 Independently selected from the group consisting of 2-naphthylmethyl, 1-naphthylmethyl, tert-butyldimethylsilyl, tert-butyldiphenylsilyl, triisopropylsilyl, triethylsilyl, benzyl, p-methoxybenzyl, benzyl substituted with halogen or C1-C6 linear or branched alkyl.

9. A use of a compound of formula M as claimed in claim 7, characterized in that Used for preparing C-nucleoside derivatives, or used as an intermediate for preparing C-nucleoside derivatives.

10. A method for preparing a compound of formula 6 or remdesivir, characterized in that: The method comprises the steps of: using the compound of formula M as claimed in claim 7 as an intermediate or raw material in a preparation process;